LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA Confirms Shortage Over For Lilly’s Weight Loss Drugs; Copies Must Come Off Market
A lawsuit forced the FDA to reassess its ruling on the availability of tirzepatide, the active ingredient in the popular drugs Mounjaro and Zepbound from Eli Lilly. As a result, the agency also told pharmacies and online companies selling off-brand copies of those drugs that they must come off the market.
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
FDA Says Knockoff Versions of Lilly Obesity Drug Must Come off the Market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes
Lilly Weight-Loss Drug Shortage in US Has Ended, FDA Says
Eli Lilly & Co.’s weight-loss and diabetes drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making copycats in the coming months.
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli Lilly’s (LLY) popular diabetes and weight-loss drugs Mounjaro and Zepbound — is officially over.
Lilly’s US weight-loss drug shortage ends, curtailing copycats
Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat versions in the coming months.
FDA keeps Mounjaro off shortage list after reevaluation
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
FDA says tirzepatide shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
MedPage Today13h
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
FiercePharma21h
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
PharmiWeb1d
Best Mounjaro Alternative Over the Counter: Cheaper, Safer Alternatives to Tirzepatide OTC
If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / If you've been following ...